Panuveitis Treatment Market Report 2026

Panuveitis Treatment Market Overview

• Panuveitis Treatment market size has reached to $4.35 billion in 2025 • Expected to grow to $6.88 billion in 2030 at a compound annual growth rate (CAGR) of 9.8% • Growth Driver: Impact of Rising Autoimmune Disorder Prevalence on the Growth of the Panuveitis Treatment Market • Market Trend: Clearside Biomedical Inc. Revolutionizes Panuveitis Treatment With Innovative Xipere Product • North America was the largest region in 2025.

What Is Covered Under Panuveitis Treatment Market?

Panuveitis is a severe inflammation of all layers of the eye's uvea, including the iris, ciliary body, and choroid, which can affect the retina, vitreous humor, optic nerve, or eye lens. Panuveitis treatment is essential to reduce inflammation, alleviate symptoms, and prevent vision loss or complications associated with the disease. The main drug classes of panuveitis treatment are anti-inflammatory, antimicrobial drugs, immunotherapy, and targeted therapies. Anti-inflammatory refers to substances or treatments that are designed to reduce inflammation in the body. The various routes of administration include oral and topical. These are used by various end-users such as hospitals, home care, specialty clinics, and others.

What Is The Panuveitis Treatment Market Growth Forecast?

The panuveitis treatment market size is expected to see strong growth in the next few years. It will grow to $6.88 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to advancements in biologic and immunotherapy drugs, increasing prevalence of autoimmune and infectious eye disorders, growth of teleophthalmology and digital monitoring, rising investments in ai-based diagnostics, expansion of hospital and specialty clinic distribution channels. Major trends in the forecast period include rising adoption of biologic and targeted therapies, integration of teleophthalmology and remote monitoring, ai-assisted diagnostic tools for uveitis, growth of personalized eye care solutions, expansion of specialized ophthalmology centers.

Global Panuveitis Treatment Market Segmentation

1) By Drug Class: Anti-Inflammatory, Antimicrobial Drugs, Immunotherapy And Targeted Therapies 2) By Route Of Administration: Oral, Topical 3) By End Users: Hospitals, Home Care, Specialty Clinics, Other End Users Subsegments: 1) By Anti-Inflammatory: Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 2) By Antimicrobial Drugs: Antibiotics, Antifungal Agents, Antiviral Medications 3) By Immunotherapy And Targeted Therapies: Biologic Agents, Janus Kinase (JAK) Inhibitors, Cytokine Modulators

What Is The Driver Of The Panuveitis Treatment Market?

Rising prevalence of autoimmune disorders is expected to propel the growth of the panuveitis treatment market going forward. Autoimmune disorders are on the rise due to a combination of genetic predispositions, environmental factors like pollution and dietary changes, and increased exposure to certain infections and stressors that may trigger immune system dysregulation. Autoimmune disorders contribute to advancements in panuveitis treatment by driving research into immune system modulation, as many panuveitis cases are related to autoimmune activity. For instance, in May 2023, according to the University of Oxford, a UK-based research university, autoimmune disorders affect 10% of the world's population, with 13% of women and 7% of males affected. Therefore, rising prevalence of autoimmune disorders is driving the growth of the panuveitis treatment industry.

Key Players In The Global Panuveitis Treatment Market

Major companies operating in the panuveitis treatment market are Pfizer Inc., Johnson and Johnson Pvt. Ltd., Bausch Health Companies Inc., AbbVie Inc., Novartis AG, Allergan Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., EyeGate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Graybug Vision Inc., Aciont Inc., Clearside Biomedical Inc., Aldeyra Therapeutics Inc., UCB S.A., Amgen Inc., Sanofi S.A., Galapagos NV, Kiora Pharmaceuticals Inc., ONL Therapeutics, Eyevensys, Nicox S.A., Abbott Laboratories

Global Panuveitis Treatment Market Trends and Insights

Major companies operating in the panuveitis treatment market are focusing on developing innovative products, such as oral dual TYK2/JAK1 inhibitors, to gain a competitive advantage. This class of small-molecule immunomodulator suppresses multiple pro-inflammatory cytokine pathways, reducing intraocular inflammation while offering the convenience of oral dosing. For instance, in April 2024, Priovant Therapeutics, a US-based biotech, announced that its oral agent brepocitinib, which inhibits TYK2 and JAK1, showed strong efficacy in a mid-stage clinical study in non-infectious uveitis, reducing macular edema in several patients. The key advantages include broad cytokine inhibition, daily oral administration, and reduced reliance on intravitreal injections. However, the risks include potential systemic immunosuppression and off-target effects, which require careful long-term monitoring.

What Are Latest Mergers And Acquisitions In The Panuveitis Treatment Market?

In July 2023, Harrow Health Inc., a US-based company, acquired Santen for an undisclosed amount. With this acquisition, Harrow aims to expand its portfolio by incorporating Santen's expertise in providing innovative treatments for uveitis and panuveitis. Santen Pharmaceutical Co. Ltd. is a Japan-based company that offers treatments for panuveitis.

Regional Outlook

North America was the largest region in the panuveitis treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Panuveitis Treatment Market?

The panuveitis treatment market consists of revenues earned by entities by providing services such as immunosuppressive therapy, adjunctive therapies, and laser therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The panuveitis treatment market also includes sales of corticosteroids, biogenic agents, and intravitreal implants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Panuveitis Treatment Market Report 2026?

The panuveitis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the panuveitis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.